AcquisitionsMay 6, 2026, 09:03 AM
NEXGEL Secures $5.5M Investment for Celularity Acquisition
AI Summary
NEXGEL, Inc. announced the appointment of Brian J. Kieser, CPA, and Kevin Harris, CFA, to its Board of Directors. Mr. Kieser and Mr. Harris are the CEO and COO of Sequence LifeScienceTM, which recently led the financing to close on NEXGEL's acquisition of Celularity Inc.’s degenerative disease segment with a $5.5 million strategic investment. This move strengthens the partnership between NEXGEL and Sequence LifeScienceTM, bringing valuable industry experience and distribution capabilities to support NEXGEL's growth and expansion following the acquisition.
Key Highlights
- NEXGEL appointed Brian J. Kieser, CPA, and Kevin Harris, CFA, to its Board of Directors.
- Mr. Kieser is CEO and Mr. Harris is COO of Sequence LifeScienceTM.
- Sequence LifeScienceTM led financing for NEXGEL's acquisition of Celularity Inc.'s degenerative disease segment.
- The strategic investment by Sequence LifeScienceTM for the acquisition was $5.5 million.
- The new directors bring industry experience, product innovation, and a strong distribution system.